The ranking covers 100 assignees across 1,096 records, with the leading company holding 118 records — well ahead of the fifth-place holder at 38 and tenth place at 21. That said, the top 5 combined account for only 27.5% of all records in scope, so no single organisation controls the field; a large share of activity sits with smaller filers, university groups and single-product entrants further down the ranking. Anyone doing competitive tracking should watch beyond the leaders, since the long tail contains a meaningful share of the total filing activity.

On complete-year data, filings grew from 62 in 2021 to 68 in 2024, a 10% increase, following an earlier peak of 104 filings in 2020. The apparent drop-off in 2025 and 2026 is a publication-lag artefact — patent applications typically take around 18 months to publish, so the newest years in any dataset always look artificially thin. Treat 2024 as the last reliable complete year and read anything after it as a floor rather than an accurate current figure.

G01N (material analysis and testing) appears in 64.3% of the 1,096 records, making it the dominant classification, but a substantial share also carries A61K medicinal-preparation classifications (33.9%) and C07K peptide/protein chemistry (23.2%). This overlap indicates that assay-method claims are frequently filed alongside reagent formulation and biologic-component claims rather than in isolation. Smaller but active adjacent classes include C12N microorganism/genetic engineering (9.9%) and C12Q enzyme/DNA measurement (9.4%), both worth checking if a filing touches biologic reagents.

Based on the IPC composition and the search terms used to build this corpus, directional antibody conjugation, bead surface functionalization chemistry, and signal-to-noise optimisation at low analyte concentrations all carry noticeably fewer dedicated records than the core assay-method claims concentrated in G01N. Wash-step automation for multiplexed panels and incubation-time reduction protocols also show thinner coverage. These branches are candidates for a first claim rather than a crowded filing, though a full novelty search against the specific claim language is still required before committing.

This 2025 filing from the Academy of National Food and Strategic Reserves Administration claims a magnetic chemiluminescence immunoassay kit for mycotoxins built around a bifunctional nanobody-alkaline phosphatase fusion protein, streptavidin magnetic particles and a direct-in-oil sample workflow that skips extraction and centrifugation. It is specific to the mycotoxin target and the fusion-protein architecture rather than to magnetic bead chemiluminescent immunoassay generally, so it constrains close variants on that particular reagent design more than it blocks the broader field. Anyone working on a similar fusion-protein or direct-matrix approach for a different analyte should still review its claim scope in detail.